Publications by authors named "Alyssa La Belle"
Role of Platinum in Early-Stage Triple-Negative Breast Cancer.
Curr Treat Options Oncol
November 2017
Triple-negative breast cancer (TNBC) is both a clinically and genomically heterogeneous disease, with distinct molecular subtypes; however, most epidemiologic and clinical studies to date have defined it under a "one disease" umbrella. This is an important point, since one therapeutic approach for all TNBCs is unlikely to be successful given the underlying biological diversity. In this review, we explore the role of platinums in the treatment of TNBC, as well as the potential for biomarkers to predict patient response to these agents.
View Article and Find Full Text PDFArticle Synopsis
- A majority of ovarian and non-small cell lung adenocarcinoma cancers produce high levels of folate receptor α (FRα), which is targeted by a new anti-FRα antibody-drug conjugate (ADC) called IMGN853.
- IMGN853 combines a specific antibody (M9346A) with a potent drug that disrupts cell microtubules, leading to cell-cycle arrest and death in FRα-positive cancer cells.
- The ADC demonstrated strong effectiveness in preclinical models and has potential for treating tumors that express FRα, along with the ability to target nearby FRα-negative cells, making it a promising option for patients with these types of cancers.
Lorvotuzumab mertansine (LM) is an antibody-drug conjugate composed of a humanized anti-CD56 antibody, lorvotuzumab, linked via a cleavable disulfide linker to the tubulin-binding maytansinoid DM1. CD56 is expressed on most small cell lung cancers (SCLC), providing a promising therapeutic target for treatment of this aggressive cancer, which has a poor five-year survival rate of only 5-10%. We performed immunohistochemical staining on SCLC tumor microarrays, which confirmed that CD56 is expressed at high levels on most (~74%) SCLC tumors.
View Article and Find Full Text PDF